Yes, the equity shares of ADC Therapeutics (ADCT) exhibit high volatility, which is characteristic of micro-cap and small-cap clinical-stage biotechnology stocks. Its share valuation fluctuates significantly based on clinical trial updates, regulatory review announcements from agencies like the FDA, quarterly financial earnings reports, and broader market sentiment toward the biotechnology sector, exposing short-term traders to sharp price movements.